Viewray Inc (NASDAQ:VRAY) shares gapped up before the market opened on Friday . The stock had previously closed at $9.05, but opened at $9.42. Viewray shares last traded at $9.50, with a volume of 2356025 shares traded.

A number of analysts have recently weighed in on the company. BTIG Research reaffirmed a “buy” rating and set a $14.00 price objective on shares of Viewray in a research report on Tuesday, August 7th. Mizuho reaffirmed a “buy” rating and set a $13.00 price objective on shares of Viewray in a research report on Monday, August 6th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $13.00 price objective on shares of Viewray in a research report on Wednesday, October 3rd. ValuEngine raised Viewray from a “hold” rating to a “buy” rating in a research report on Wednesday, July 4th. Finally, Jefferies Financial Group assumed coverage on Viewray in a research report on Tuesday, July 3rd. They set a “buy” rating and a $12.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $12.79.

The company has a quick ratio of 2.64, a current ratio of 3.33 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of $712.96 million, a price-to-earnings ratio of -9.50 and a beta of 1.10.

Viewray (NASDAQ:VRAY) last posted its quarterly earnings data on Friday, August 3rd. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). Viewray had a negative return on equity of 353.05% and a negative net margin of 83.84%. The company had revenue of $16.44 million for the quarter, compared to analysts’ expectations of $15.97 million. During the same period in the prior year, the company posted ($0.15) EPS. The firm’s revenue was up 2255.3% compared to the same quarter last year. Analysts predict that Viewray Inc will post -0.8 earnings per share for the current fiscal year.

In related news, major shareholder Orbimed Advisors Llc sold 1,368,796 shares of the stock in a transaction on Friday, August 10th. The stock was sold at an average price of $9.97, for a total value of $13,646,896.12. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder International Ltd Fosun bought 2,702,702 shares of the company’s stock in a transaction that occurred on Thursday, August 30th. The stock was acquired at an average cost of $9.25 per share, for a total transaction of $24,999,993.50. The disclosure for this purchase can be found here. Insiders have sold 3,436,496 shares of company stock worth $36,326,958 in the last ninety days. Corporate insiders own 43.93% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Fosun International Ltd increased its holdings in Viewray by 27.9% in the second quarter. Fosun International Ltd now owns 13,768,556 shares of the company’s stock valued at $95,278,000 after buying an additional 3,000,581 shares during the last quarter. FMR LLC increased its holdings in Viewray by 36.9% in the second quarter. FMR LLC now owns 7,670,767 shares of the company’s stock valued at $53,082,000 after buying an additional 2,069,086 shares during the last quarter. BlackRock Inc. increased its holdings in Viewray by 59.3% in the second quarter. BlackRock Inc. now owns 2,962,937 shares of the company’s stock valued at $20,503,000 after buying an additional 1,102,991 shares during the last quarter. RTW Investments LP increased its holdings in Viewray by 8.5% in the second quarter. RTW Investments LP now owns 1,474,156 shares of the company’s stock valued at $10,201,000 after buying an additional 115,445 shares during the last quarter. Finally, Artisan Partners Limited Partnership purchased a new position in Viewray in the second quarter valued at $6,852,000. 91.45% of the stock is currently owned by hedge funds and other institutional investors.

Viewray Company Profile (NASDAQ:VRAY)

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

See Also: Penny Stocks, Risk and Reward Factors

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.